Detalhe da pesquisa
1.
Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Int J Cancer
; 144(6): 1453-1459, 2019 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30155893
2.
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Ann Oncol
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490358
3.
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 33(3): 244-258, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861372
4.
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Ann Oncol
; 27(7): 1311-6, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091807
5.
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Front Oncol
; 13: 1246603, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37711193
6.
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.
Sci Rep
; 10(1): 10952, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32616859
7.
FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
Int Urol Nephrol
; 49(9): 1585-1591, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28674853
8.
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.
Sci Rep
; 7(1): 5554, 2017 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28717136